BB Biotech (BION) investor relations material

Executive summary

• Q1 2026 net loss narrowed to CHF 21 million from CHF 241 million in Q1 2025, reflecting improved portfolio positioning and market conditions.

• Share price delivered total returns of +4.1% (CHF), +5.2% (EUR), and +3.2% (USD), outperforming the Nasdaq Biotech Index in all currencies.

• Discount to NAV narrowed from 10.8% at year-end 2025 to 6.9% at March 31, 2026.

• Portfolio expanded from 24 to 30 holdings with 11 new investments, increasing diversification across oncology, rare diseases, immunology, and cardiometabolic medicine.

• Dividend of CHF 2.25 per share for 2025 paid in March 2026; inclusion in SPI Select Dividend 20 Index highlights commitment to shareholder returns.

Financial highlights

• Share price at period end: CHF 44.45 (EUR 48.50); NAV per share: CHF 47.75; Market capitalization: CHF 2,462.5 mn; Net Asset Value: CHF 2,633.3 mn.

• Share price outperformed NAV by 4.7 percentage points in CHF, narrowing the market discount.

• NAV performance: -0.6% (CHF), +0.1% (EUR), -1.5% (USD) for Q1 2026.

• Total expense ratio (TER): 1.37% p.a. based on market capitalization.

• Earnings per share: CHF -0.39 (Q1 2025: CHF -4.40).

Outlook and guidance

• Portfolio positioned for multiple near-term catalysts, including FDA decisions and pivotal clinical data readouts in 2026.

• Macro environment remains dynamic with ongoing trade policy uncertainty, geopolitical shifts, and evolving interest rates.

• Continued focus on diversification, innovation, and integration of AI-enabled investment processes.

• M&A activity anticipated to accelerate as biopharma seeks to offset patent expirations.